The IAH1 Knockout NCI-H1975 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the IAH1 gene, which encodes inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1). This heterogeneous pool avoids clonal artifacts and enables robust assessment of ITIH1 function in a non-small cell lung cancer context, focusing on extracellular matrix biology and cancer cell behavior.
NCI-H1975 is an epithelial non-small cell lung cancer line derived from a female adenocarcinoma patient and harbors EGFR T790M and L858R mutations. These mutations drive oncogenic signaling and confer acquired resistance to first-generation tyrosine kinase inhibitors, making the line a clinically relevant model for EGFR-mutant lung adenocarcinoma with focus on drug resistance and metastasis.
IAH1 encodes the ITIH1 heavy chain of the inter-alpha-trypsin inhibitor (ITI) complex, which stabilizes the extracellular matrix by covalently linking to hyaluronan via TSG-6. Within the ITI complex, ITIH1 interacts with bikunin, ITIH2, and ITIH3, and its transfer to hyaluronan forms a matrix that binds CD44 and inhibits serine proteases such as plasmin. IAH1 expression is regulated by pro-inflammatory cytokines including IL-6, TNF, TGF-??, and IL-1??, and the transcription factor HNF4A. Downstream, IAH1 influences TSG-6-mediated hyaluronan modification, plasmin inhibition, and matrix metalloproteinase activity, thereby controlling ECM remodeling and cell motility.
In the NCI-H1975 background, IAH1 knockout likely disrupts ECM integrity, reducing hyaluronan crosslinking and enhancing matrix metalloproteinase activity, which may increase cell migration and invasion. This model is valuable for dissecting how ECM remodeling and inflammatory signaling influence EGFR inhibitor resistance and metastatic progression in lung adenocarcinoma.
These polyclonal knockout cells are suitable for investigating ECM remodeling in EGFR-mutant lung cancer, hyaluronan-dependent invasion, and sensitivity to EGFR TKIs. Standard assays include Western blot for ITIH1, Transwell migration and invasion assays, immunofluorescence for hyaluronan and TSG-6, ELISA for inter-alpha-inhibitor activity, RT-qPCR for ITIH1 and bikunin, and drug sensitivity assays with EGFR inhibitors. For further information, please contact Ascent Research.
